SGAM
IOVA icon

Smith Group Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Smith Group Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,150
Closed -$114K – 323
2020
Q2 		$114K Sell
4,150
-40
-1% -$1.31K 0.01% 188
2020
Q1 		$125K Hold
4,190
– – 0.01% 195
2019
Q4 		$116K Hold
4,190
– – ﹤0.01% 234
2019
Q3 		$76K Buy
+4,190
New +$92.7K ﹤0.01% 251

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Smith Group Asset Management's IOVA Position: Q3 2020 in Review

Smith Group Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 4,150 shares — an estimated $114K sold.

Smith Group Asset Management first reported a position in IOVA in Q3 2019 and held it in 4 quarters. The position peaked at $125K in Q1 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • Smith Group Asset Management reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Smith Group Asset Management sold 4,150 Iovance Biotherapeutics shares in Q3 2020, an estimated $114K.
  • Smith Group Asset Management first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 4 quarters.
  • Smith Group Asset Management's Iovance Biotherapeutics position peaked at $125K in Q1 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on Smith Group Asset Management's 13F filing for Q3 2020, filed 4 Nov 2020.